broad_id
string | depmap_id
string | ccle_name
string | screen_id
string | upper_limit
int64 | lower_limit
float64 | slope
float64 | r2
float64 | auc
float64 | ec50
float64 | ic50
float64 | name
string | moa
string | target
string | disease.area
string | indication
string | smiles
string | phase
string | passed_str_profiling
bool | row_name
string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BRD-K71847383-001-12-5 | ACH-000997 | HCT15_LARGE_INTESTINE | HTS002 | 1 | 1.994732 | -0.33296 | 0.078886 | 1.268608 | 0.002225 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000997 |
BRD-K71847383-001-12-5 | ACH-000796 | MCAS_OVARY | HTS002 | 1 | 1.25198 | -0.27718 | 0.072106 | 1.144227 | 0.260595 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000796 |
BRD-K71847383-001-12-5 | ACH-000652 | SUIT2_PANCREAS | HTS002 | 1 | 1.499845 | -0.505386 | 0.087659 | 1.210729 | 0.031479 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000652 |
BRD-K71847383-001-12-5 | ACH-000452 | TE8_OESOPHAGUS | HTS002 | 1 | 2.003247 | 0.056744 | -0.073328 | 1.110838 | 855,286,071,319,097 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000452 |
BRD-K71847383-001-12-5 | ACH-000458 | CJM_SKIN | HTS002 | 1 | 1.82961 | -0.199557 | -0.059521 | 1.177013 | 0.000073 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000458 |
BRD-K71847383-001-12-5 | ACH-000221 | SNU398_LIVER | HTS002 | 1 | 1.692101 | -0.105804 | -0.032783 | 1.324933 | 0.024001 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000221 |
BRD-K71847383-001-12-5 | ACH-000893 | NCIH1651_LUNG | HTS002 | 1 | 1.703654 | -1.629463 | 0.233551 | 1.292357 | 0.034376 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000893 |
BRD-K71847383-001-12-5 | ACH-000769 | LK2_LUNG | HTS002 | 1 | 2.03336 | -0.186315 | -0.083701 | 1.177114 | 0.00001 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000769 |
BRD-K71847383-001-12-5 | ACH-000384 | SW780_URINARY_TRACT | HTS002 | 1 | 2.251179 | -0.18211 | -0.014301 | 1.535935 | 0.014475 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000384 |
BRD-K71847383-001-12-5 | ACH-000505 | RKN_SOFT_TISSUE | HTS002 | 1 | 1.399973 | -0.043894 | -0.024252 | 1.265641 | 460,741.309035 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000505 |
BRD-K71847383-001-12-5 | ACH-000858 | KNS62_LUNG | HTS002 | 1 | 1.699276 | -0.158806 | -0.041523 | 1.431616 | 1.829325 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000858 |
BRD-K71847383-001-12-5 | ACH-000595 | LN229_CENTRAL_NERVOUS_SYSTEM | HTS002 | 1 | 2.017723 | -0.066867 | 0.041406 | 1.462138 | 0.004856 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000595 |
BRD-K71847383-001-12-5 | ACH-000052 | A673_BONE | HTS002 | 1 | 2.141329 | -0.864391 | 0.053429 | 1.135017 | 0.001126 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000052 |
BRD-K71847383-001-12-5 | ACH-000979 | DU145_PROSTATE | HTS002 | 1 | 1.221788 | 0.128296 | -0.074305 | 1.120404 | 0.019596 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000979 |
BRD-K71847383-001-12-5 | ACH-000571 | T98G_CENTRAL_NERVOUS_SYSTEM | HTS002 | 1 | 1.147221 | -0.069898 | -0.019076 | 1.089857 | 50.995274 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000571 |
BRD-K71847383-001-12-5 | ACH-000812 | COLO783_SKIN | HTS002 | 1 | 1.641008 | -0.169968 | -0.01765 | 1.291851 | 0.025651 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000812 |
BRD-K71847383-001-12-5 | ACH-000667 | HCC44_LUNG | HTS002 | 1 | 0.937488 | 1.371578 | -0.106352 | 0.96864 | 0.07687 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000667 |
BRD-K71847383-001-12-5 | ACH-000734 | JHH5_LIVER | HTS002 | 1 | 0.837606 | -0.531712 | -0.050478 | 0.909126 | 0.153441 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000734 |
BRD-K71847383-001-12-5 | ACH-000416 | NCIH838_LUNG | HTS002 | 1 | 1.468118 | -0.335735 | 0.292732 | 1.208331 | 0.035238 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000416 |
BRD-K71847383-001-12-5 | ACH-000802 | BFTC905_URINARY_TRACT | HTS002 | 1 | 1.748714 | -0.424352 | 0.169669 | 1.172676 | 0.002 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000802 |
BRD-K71847383-001-12-5 | ACH-000946 | HEC265_ENDOMETRIUM | HTS002 | 1 | 2.034495 | -0.019273 | -0.065073 | 1.582932 | 44,772.752872 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000946 |
BRD-K71847383-001-12-5 | ACH-000472 | HSC2_UPPER_AERODIGESTIVE_TRACT | HTS002 | 1 | 1.828404 | -0.479246 | 0.158898 | 1.193562 | 0.002651 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000472 |
BRD-K71847383-001-12-5 | ACH-000962 | OC314_OVARY | HTS002 | 1 | 1.788741 | -0.394878 | 0.087363 | 1.160484 | 0.001051 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000962 |
BRD-K71847383-001-12-5 | ACH-000383 | OE33_OESOPHAGUS | HTS002 | 1 | 1.744051 | -0.070923 | 0.026437 | 1.344814 | 0.009696 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000383 |
BRD-K71847383-001-12-5 | ACH-001307 | 8505C_THYROID | HTS002 | 1 | 1.663295 | -0.113976 | -0.067773 | 1.30651 | 0.019925 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-001307 |
BRD-K71847383-001-12-5 | ACH-000756 | GI1_CENTRAL_NERVOUS_SYSTEM | HTS002 | 1 | 1.563666 | -3.018438 | 0.109852 | 1.349521 | 0.250541 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000756 |
BRD-K71847383-001-12-5 | ACH-000444 | LU99_LUNG | HTS002 | 1 | 2.126472 | -0.296368 | 0.334779 | 1.355573 | 0.003797 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000444 |
BRD-K71847383-001-12-5 | ACH-000142 | CAL29_URINARY_TRACT | HTS002 | 1 | 1.860068 | -0.134613 | 0.071368 | 1.292663 | 0.000483 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000142 |
BRD-K71847383-001-12-5 | ACH-000905 | 5637_URINARY_TRACT | HTS002 | 1 | 1.256622 | -0.103827 | -0.056188 | 1.215072 | 773,672.515026 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000905 |
BRD-K71847383-001-12-5 | ACH-000954 | HEC1A_ENDOMETRIUM | HTS002 | 1 | 1.381142 | -2.850046 | 0.032335 | 1.222815 | 0.177552 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000954 |
BRD-K71847383-001-12-5 | ACH-000280 | SNU840_OVARY | HTS002 | 1 | 1.34452 | -0.37879 | 0.206395 | 1.120403 | 0.009931 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000280 |
BRD-K71847383-001-12-5 | ACH-000012 | HCC827_LUNG | HTS002 | 1 | 1.348043 | -0.841814 | 0.151777 | 1.134724 | 0.025008 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000012 |
BRD-K71847383-001-12-5 | ACH-000098 | GAMG_CENTRAL_NERVOUS_SYSTEM | HTS002 | 1 | 2.704692 | 0.161359 | 0.015745 | 1.605352 | 3.779913 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000098 |
BRD-K71847383-001-12-5 | ACH-000589 | NCIH1437_LUNG | HTS002 | 1 | 1.128672 | 0.176667 | -0.052735 | 1.09157 | 0.000352 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000589 |
BRD-K71847383-001-12-5 | ACH-000837 | NCIH322_LUNG | HTS002 | 1 | 1.421651 | 0.003669 | 0.00038 | 1.194987 | 51,316,967,897,241,890 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000837 |
BRD-K71847383-001-12-5 | ACH-000967 | SNUC2A_LARGE_INTESTINE | HTS002 | 1 | 4.333276 | -2.309807 | 0.14226 | 1.036756 | 0.000352 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000967 |
BRD-K71847383-001-12-5 | ACH-000662 | CORL23_LUNG | HTS002 | 1 | 1.593196 | -0.16488 | 0.0017 | 1.351199 | 0.841244 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000662 |
BRD-K71847383-001-12-5 | ACH-000537 | SNU761_LIVER | HTS002 | 1 | 1.449239 | 0.378915 | -0.110021 | 1.339953 | 0.001912 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000537 |
BRD-K71847383-001-12-5 | ACH-000427 | NCIN87_STOMACH | HTS002 | 1 | 2.1089 | -3.988526 | 0.248892 | 1.668714 | 0.21235 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000427 |
BRD-K71847383-001-12-5 | ACH-000774 | RERFLCAD2_LUNG | HTS002 | 1 | 1.233871 | 0.109776 | -0.056084 | 1.131919 | 0.007071 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000774 |
BRD-K71847383-001-12-5 | ACH-000624 | HCC1806_BREAST | HTS002 | 1 | 1.307852 | -0.014875 | -0.03995 | 1.23353 | 215,825,847,661,541,000,000,000,000,000,000 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000624 |
BRD-K71847383-001-12-5 | ACH-000888 | NCIH1793_LUNG | HTS002 | 1 | 1.390129 | -0.260693 | -0.0221 | 1.119931 | 0.002363 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000888 |
BRD-K71847383-001-12-5 | ACH-000587 | NCIH1975_LUNG | HTS002 | 1 | 1.437921 | -0.236394 | 0.069151 | 1.194195 | 0.026967 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000587 |
BRD-K71847383-001-12-5 | ACH-000404 | K029AX_SKIN | HTS002 | 1 | 1.809758 | -0.196466 | 0.08881 | 1.396361 | 0.062062 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000404 |
BRD-K71847383-001-12-5 | ACH-000813 | T3M10_LUNG | HTS002 | 1 | 1.584868 | -1.296413 | 0.015067 | 1.410132 | 0.560717 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000813 |
BRD-K71847383-001-12-5 | ACH-000311 | NCIH2122_LUNG | HTS002 | 1 | 0.884677 | 8.555614 | -0.370214 | 0.925848 | 0.019505 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000311 |
BRD-K71847383-001-12-5 | ACH-000849 | MDAMB468_BREAST | HTS002 | 1 | 1.865268 | -0.310476 | 0.110086 | 1.308948 | 0.008407 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000849 |
BRD-K71847383-001-12-5 | ACH-000868 | HCC1195_LUNG | HTS002 | 1 | 2.169308 | -0.392395 | -0.018196 | 1.161877 | 0.000265 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000868 |
BRD-K71847383-001-12-5 | ACH-000978 | EN_ENDOMETRIUM | HTS002 | 1 | 0.905566 | 2.370776 | 0.040483 | 0.932933 | 0.010155 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000978 |
BRD-K71847383-001-12-5 | ACH-000408 | TE5_OESOPHAGUS | HTS002 | 1 | 1.485686 | -0.42641 | 0.173337 | 1.293596 | 0.29279 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000408 |
BRD-K71847383-001-12-5 | ACH-000344 | SNU668_STOMACH | HTS002 | 1 | 1.590552 | -0.176094 | -0.081815 | 1.225685 | 0.004347 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000344 |
BRD-K71847383-001-12-5 | ACH-000835 | GCT_SOFT_TISSUE | HTS002 | 1 | 1.409145 | -0.083691 | -0.097148 | 1.251747 | 23.051623 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000835 |
BRD-K71847383-001-12-5 | ACH-000819 | LN18_CENTRAL_NERVOUS_SYSTEM | HTS002 | 1 | 1.406103 | -0.790645 | -0.140204 | 1.217826 | 0.11297 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000819 |
BRD-K71847383-001-12-5 | ACH-000062 | RERFLCMS_LUNG | HTS002 | 1 | 1.588812 | 0.163852 | -0.110685 | 1.366039 | 0.003231 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000062 |
BRD-K71847383-001-12-5 | ACH-000473 | RT112_URINARY_TRACT | HTS002 | 1 | 1.820227 | -0.242808 | -0.048699 | 1.158452 | 0.000123 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000473 |
BRD-K71847383-001-12-5 | ACH-000176 | LOUNH91_LUNG | HTS002 | 1 | 1.329275 | -0.520574 | 0.013645 | 1.141415 | 0.034871 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000176 |
BRD-K71847383-001-12-5 | ACH-000445 | KNS60_CENTRAL_NERVOUS_SYSTEM | HTS002 | 1 | 1.85368 | -0.061979 | -0.009423 | 1.416066 | 0.034381 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000445 |
BRD-K71847383-001-12-5 | ACH-000163 | SW579_THYROID | HTS002 | 1 | 2.731411 | 0.147951 | 0.090398 | 1.431601 | 179.501087 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000163 |
BRD-K71847383-001-12-5 | ACH-000768 | MDAMB231_BREAST | HTS002 | 1 | 1.71411 | 0.005614 | -0.02155 | 1.357343 | 0.058587 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000768 |
BRD-K71847383-001-12-5 | null | null | HTS002 | 1 | 1.548309 | -1.400305 | 0.098126 | 1.390421 | 0.620406 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | false | ACH-001078_FAILED_STR |
BRD-K71847383-001-12-5 | ACH-000778 | HSC3_UPPER_AERODIGESTIVE_TRACT | HTS002 | 1 | 2.085401 | -0.423147 | 0.535338 | 1.261748 | 0.002354 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000778 |
BRD-K71847383-001-12-5 | ACH-000881 | MELJUSO_SKIN | HTS002 | 1 | 1.793375 | -0.245927 | 0.217586 | 1.275193 | 0.004467 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000881 |
BRD-K71847383-001-12-5 | ACH-000521 | NCIH2030_LUNG | HTS002 | 1 | 2.036625 | -0.123593 | 0.193966 | 1.372149 | 0.000626 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000521 |
BRD-K71847383-001-12-5 | ACH-000696 | OVCAR8_OVARY | HTS002 | 1 | 1.758375 | -0.120137 | 0.152999 | 1.29751 | 0.001848 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000696 |
BRD-K71847383-001-12-5 | ACH-000972 | HEC151_ENDOMETRIUM | HTS002 | 1 | 1.390425 | 2.512651 | 0.048176 | 1.249867 | 0.020082 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000972 |
BRD-K71847383-001-12-5 | ACH-000242 | RT4_URINARY_TRACT | HTS002 | 1 | 1.401589 | -0.024238 | -0.036265 | 1.239152 | 678,504.78873 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000242 |
BRD-K71847383-001-12-5 | ACH-000087 | SKES1_BONE | HTS002 | 1 | 1.602363 | 5.852604 | -0.112031 | 1.250667 | 0.176282 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000087 |
BRD-K71847383-001-12-5 | ACH-000926 | HT55_LARGE_INTESTINE | HTS002 | 1 | 1.531283 | 0.026866 | -0.043882 | 1.264591 | 0.104928 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000926 |
BRD-K71847383-001-12-5 | ACH-000356 | MKN45_STOMACH | HTS002 | 1 | 2.480268 | -0.717228 | 0.281591 | 1.224747 | 0.001474 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000356 |
BRD-K71847383-001-12-5 | ACH-000625 | HEP3B217_LIVER | HTS002 | 1 | 1.334807 | -0.019106 | -0.0182 | 1.181092 | 417.927701 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000625 |
BRD-K71847383-001-12-5 | ACH-000613 | HOS_BONE | HTS002 | 1 | 1.541669 | -4.432632 | 0.333643 | 1.35293 | 0.340037 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000613 |
BRD-K71847383-001-12-5 | ACH-000976 | HUCCT1_BILIARY_TRACT | HTS002 | 1 | 1.536963 | -0.024777 | -0.040402 | 1.258142 | 0.003471 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000976 |
BRD-K71847383-001-12-5 | ACH-001075 | NCIH292_LUNG | HTS002 | 1 | 1.18518 | 0.033302 | -0.070894 | 1.101319 | 0.000264 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-001075 |
BRD-K71847383-001-12-5 | ACH-000261 | RERFLCAI_LUNG | HTS002 | 1 | 1.278797 | -0.310586 | 0.076275 | 1.142018 | 0.090141 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000261 |
BRD-K71847383-001-12-5 | ACH-000957 | LS180_LARGE_INTESTINE | HTS002 | 1 | 1.6274 | -0.283156 | 0.096123 | 1.239714 | 0.011097 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000957 |
BRD-K71847383-001-12-5 | ACH-000099 | SIMA_AUTONOMIC_GANGLIA | HTS002 | 1 | 1.415598 | 0.07602 | -0.091357 | 1.269836 | 0.000022 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000099 |
BRD-K71847383-001-12-5 | ACH-000783 | CAMA1_BREAST | HTS002 | 1 | 4.073026 | -0.364404 | -0.092349 | 1.27568 | 0.000046 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000783 |
BRD-K71847383-001-12-5 | ACH-000573 | MDAMB436_BREAST | HTS002 | 1 | 1.201314 | 0.336501 | 0.025879 | 1.079206 | 0.370127 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000573 |
BRD-K71847383-001-12-5 | ACH-000852 | NCIH1435_LUNG | HTS002 | 1 | 1.828741 | -0.000783 | -0.002569 | 1.43651 | 17,664,100,635,817,900,000,000,000,000,000,000,000,000,000,000,000,000,000,000 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000852 |
BRD-K71847383-001-12-5 | ACH-000461 | SNU1196_BILIARY_TRACT | HTS002 | 1 | 1.730753 | -0.589372 | 0.097438 | 1.498227 | 0.594516 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000461 |
BRD-K71847383-001-12-5 | ACH-000694 | TE9_OESOPHAGUS | HTS002 | 1 | 2.052918 | -0.150226 | -0.006139 | 1.503695 | 0.04282 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000694 |
BRD-K71847383-001-12-5 | ACH-000563 | EBC1_LUNG | HTS002 | 1 | 1.723233 | -0.250573 | 0.178935 | 1.381696 | 0.128412 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000563 |
BRD-K71847383-001-12-5 | ACH-000665 | SKMES1_LUNG | HTS002 | 1 | 1.842281 | -0.22964 | 0.138621 | 1.28265 | 0.002986 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000665 |
BRD-K71847383-001-12-5 | ACH-000467 | HCC56_LARGE_INTESTINE | HTS002 | 1 | 2.411235 | -0.431231 | -0.189221 | 1.509725 | 0.013454 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000467 |
BRD-K71847383-001-12-5 | ACH-000201 | A204_SOFT_TISSUE | HTS002 | 1 | 0.998533 | -0.07727 | -0.005421 | 0.999312 | 0.015245 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000201 |
BRD-K71847383-001-12-5 | ACH-000296 | OUMS23_LARGE_INTESTINE | HTS002 | 1 | 2.445326 | -0.05215 | -0.015512 | 1.637071 | 0.000795 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000296 |
BRD-K71847383-001-12-5 | ACH-000189 | RCC10RGB_KIDNEY | HTS002 | 1 | 1.356871 | -0.033364 | -0.109199 | 1.191694 | 6.840166 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000189 |
BRD-K71847383-001-12-5 | ACH-000367 | NCIH226_LUNG | HTS002 | 1 | 1.374552 | -0.041435 | -0.020854 | 1.200929 | 2.684375 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000367 |
BRD-K71847383-001-12-5 | ACH-001190 | SKMEL2_SKIN | HTS002 | 1 | 1.330897 | -1.03579 | 0.0051 | 1.142456 | 0.039422 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-001190 |
BRD-K71847383-001-12-5 | ACH-000244 | DKMG_CENTRAL_NERVOUS_SYSTEM | HTS002 | 1 | 1.530379 | -0.513204 | 0.12384 | 1.168996 | 0.009197 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000244 |
BRD-K71847383-001-12-5 | ACH-000713 | CAOV3_OVARY | HTS002 | 1 | 1.320942 | -0.137464 | -0.031319 | 1.246405 | 623.129939 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000713 |
BRD-K71847383-001-12-5 | ACH-000672 | IALM_LUNG | HTS002 | 1 | 1.507665 | -3.080093 | 0.117562 | 1.331088 | 0.342088 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000672 |
BRD-K71847383-001-12-5 | ACH-000875 | NCIH2347_LUNG | HTS002 | 1 | 1.658808 | -0.30782 | 0.06821 | 1.299522 | 0.038924 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000875 |
BRD-K71847383-001-12-5 | ACH-000423 | SKMEL3_SKIN | HTS002 | 1 | 1.30366 | -0.193639 | 0.106178 | 1.173827 | 0.392989 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000423 |
BRD-K71847383-001-12-5 | ACH-000553 | SQ1_LUNG | HTS002 | 1 | 1.695377 | -0.120277 | 0.107659 | 1.34794 | 0.079097 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000553 |
BRD-K71847383-001-12-5 | ACH-000834 | UMUC1_URINARY_TRACT | HTS002 | 1 | 3.026172 | -0.363702 | 0.136741 | 1.386334 | 0.000642 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000834 |
BRD-K71847383-001-12-5 | ACH-000123 | COV434_OVARY | HTS002 | 1 | 1.387679 | 0.022656 | -0.012454 | 1.187084 | 1.701261 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000123 |
BRD-K71847383-001-12-5 | ACH-000329 | CCFSTTG1_CENTRAL_NERVOUS_SYSTEM | HTS002 | 1 | 1.899701 | -0.14768 | 0.137474 | 1.360628 | 0.004582 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000329 |
BRD-K71847383-001-12-5 | ACH-000717 | COLO680N_OESOPHAGUS | HTS002 | 1 | 1.406076 | -0.099884 | 0.122437 | 1.188085 | 0.017326 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000717 |
BRD-K71847383-001-12-5 | ACH-000669 | SW900_LUNG | HTS002 | 1 | 1.675203 | -0.035889 | 0.008393 | 1.348505 | 0.475012 | null | cytarabine | ribonucleotide reductase inhibitor | POLA1, POLB, POLD1, POLE | hematologic malignancy | acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000669 |